Immix announces additional NXC-201 AL Amyloidosis data to be presented - TipRanks.com
Immix Biopharma's additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece, September 27-30, 2023. Dr. Polina Stepensky highlighted progress in providing new treatment options for patients.
Related Clinical Trials
Reference News
Nexcella, Inc. announced updated NXC-201 clinical data for relapsed/refractory multiple myeloma will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece. NXC-201, a BCMA-targeted CAR-T cell therapy, shows promise in treating multiple myeloma and AL amyloidosis, with ongoing Phase 1b/2a trials aiming for FDA submission.
Immix Biopharma focuses on CAR-T cell therapy for AL Amyloidosis, autoimmune diseases, and multiple myeloma, with NXC-201 in Phase Ib/IIa trials. IMX-110, in trials for advanced solid tumors, combines with tislelizumab for CRC, utilizing TME Normalization technology for mCRC and STS.
Immix Biopharma's additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece, September 27-30, 2023. Dr. Polina Stepensky highlighted progress in providing new treatment options for patients.
Nexcella, Inc. will present updated NXC-201 clinical data for relapsed/refractory multiple myeloma at the 20th International Myeloma Society Annual Meeting in Athens, September 27-30, 2023. NXC-201, a BCMA-targeted CAR-T therapy, shows promise in treating multiple myeloma and AL amyloidosis, with ongoing Phase 1b/2a trials.